Biocon Biologics, a subsidiary of Biocon, announced a settlement agreement with Amgen Inc. that clears the path for the commercialization of its Denosumab biosimilars in Europe and the rest of the world.
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo' and Evfraxy') in Europe starting 02 December 2025. The other terms of the settlement remain confidential.
Powered by Capital Market - Live News
